CRISPR screens are feasible in TP53 wild-type cells. CRISPR screens are feasible in TP53 wild-type cells

CRISPR-Cas9 genome-wide screens were performed in retinal pigment epithelial cells (RPE1) with either wild-type TP53 gene, or a TP53-null background. Results show wild-type TP53 has minimal impact on the efficiency of CRISPR dropout screens. Overall design: Five genome-wide CRISPR dropout screens are performed independently in RPE1 cells using TKOv1 (n=1), TKOv2 (n=1) or TKOv3 (n=3) CRISPR libraries. Screens were performed in duplicate (n=2) or triplicate (n=3).